- Home
- GLRE vs AVIR Comparison
GLRE vs AVIR Comparison
Compare GLRE & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | AVIR |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.7M | 413.1M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GLRE | AVIR |
|---|---|---|
| Price | $15.11 | $4.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.42 |
| AVG Volume (30 Days) | 102.2K | ★ 276.1K |
| Earning Date | 11-06-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | 3.00 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $729,777,000.00 | $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $85.06 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $2.87 |
| 52 Week High | $19.39 | $6.45 |
Technical Indicators
Market Signals| Indicator | GLRE | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 25.19 |
| Support Level | $14.53 | $3.34 |
| Resistance Level | $15.48 | $4.46 |
| Average True Range (ATR) | 0.37 | 0.24 |
| MACD | 0.06 | -0.09 |
| Stochastic Oscillator | 59.12 | 8.46 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.